Keywords: denosumab, bmd, gain, greater, fosamax, biotechnology, major

Denosumab's BMD gain greater than Fosamax

Article | 09 June 2008

US biotechnology major Amgen's denosumab provided superior gain in bone mineral density than Merck & Co's blockbuster Fosamax (alendronate), according to ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Amgen

Merck

Merck KGaA

Go to company listing

Related Drugs

Alendronate Sodium

Fosamax

Go to drug listing